← Back

Accuray Incorporated

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for treating tumors throughout the body. Its offerings include the CyberKnife platform for robotic stereotactic radiosurgery and stereotactic body radiation therapy, and the TomoTherapy platform, which features the Radixact System, iDMS data management system, and Accuray precision treatment planning system. The company also provides post-contract customer support, installation, training, and other professional services. It markets directly to hospitals and stand-alone treatment facilities, as well as through sales agents and group purchasing organizations in the United States, and through distributors and sales agents internationally. Accuray was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Price · split & dividend adjusted
News & notes moving 0H8I.LSE
0H8I.LSE▲

Accuray and RaySearch Expand Collaboration on Online Adaptive Radiation Therapy

Accuray Incorporated and RaySearch Laboratories AB have entered into a definitive agreement for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy. The collaboration combines Accuray's photon-based radiation therapy platforms and imaging capabilities with RaySearch's treatment planning and workflow software, with the initial focus on Accuray's Radixact platform and future extension to the CyberKnife platform. Under the agreement, Accuray has agreed to purchase specified RayStation licenses with a total order value of USD $8 million to support commercialization of online adaptive radiation therapy solutions, which the two parties will jointly market and support. The collaboration will also leverage RayCare technology to simplify connectivity between clinical systems, and RaySearch will further enhance its software to support the Radixact platform. RaySearch founder and CEO Johan Löf said Accuray's global presence, large installed base, differentiated technology and worldwide service capabilities made them an ideal partner, while Accuray CEO Steve LaNeve said the partnership supports the company's growth strategy and its online adaptive radiation therapy strategy.
0GRZ.LSE ▲ARAY ▲
PR Newswire·7dRead more →
0H8I.LSE

Accuray Withholds FY27 Guidance, Expects $15M Cost Improvement

Accuray announced it will not provide formal revenue or adjusted EBITDA guidance for fiscal 2027, instead expecting approximately $15 million of incremental annualized cost and margin improvement. The company reported fourth quarter net revenue of $100.9 million and full fiscal year 2026 revenue of $402 million, with a full-year operating loss of $26.4 million and adjusted EBITDA of $10.6 million. Management highlighted a comprehensive transaction with TCW Asset Management Company that includes conversion of $40 million of existing debt into preferred equity and a $15 million cash investment. Accuray also cited nonbinding letters of intent with Samsung HME America and RaySearch Laboratories, and a 10-year strategic collaboration with the University of Wisconsin School of Medicine and Public Health. The company plans to implement a reverse stock split at a ratio still to be determined and subject to stockholder approval.
ARAY
Seeking Alpha·30dRead more →
Biotech & Genomic Medicine▲2

Radiotherapy Market to Reach USD 10.68 Billion by 2031 at 6.0% CAGR

The global radiotherapy market is projected to grow from USD 7.98 billion in 2026 to USD 10.68 billion by 2031, at a CAGR of 6.0%, according to a new report by MarketsandMarkets. Growth is driven by rising cancer incidence, increased healthcare investments, and demand for precision oncology, with rapid adoption of technologies such as proton beam therapy, adaptive radiotherapy, and AI-based treatment planning. The systems segment is expected to hold the largest share, while external beam radiotherapy dominates across technology, application, and procedure segments, and hospitals remain the leading end user. Asia Pacific is forecast to register the highest CAGR, supported by expanding oncology infrastructure and government spending in countries including China, India, and Japan. Key players include Siemens Healthineers AG, Elekta, Accuray Incorporated, IBA Worldwide, and ViewRay Technologies.
0O5H.LSE ▲ARAY ▲SHL.XETRA ▲
Biotech & Genomic Medicine ▲
GlobeNewswire·58dRead more →
© 2026 MarketDXAsset